Diethanolamine

Diethanolamine

SCHEMBL632948

COc1ccc(CCC(=O)O)cc1.OCCNCCO

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGIRfolP

The experimentally established mechanism targets of Diethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.64
F2RL1 P55085 1/20 0.59
POLB P06746 1/20 0.56
FFAR4 Q5NUL3 1/20 0.54
PLAAT3 P53816 1/20 0.53
PLAAT5 Q96KN8 1/20 0.53
PLAAT2 Q9NWW9 1/20 0.53
PLAAT4 Q9UL19 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30792366 0.87 FFAR1 (0.81) FFAR1F2RL1POLBFFAR4ALDH1A1
SCHEMBL274471 0.87 FFAR1 (0.81) FFAR1F2RL1POLBFFAR4ALDH1A1
SCHEMBL3196104 0.84 MEN1 (0.62) FFAR1F2RL1POLBPLAAT3PLAAT5
SCHEMBL8880193 0.84 SMN1; SMN2 (0.57) F2RL1SMN1; SMN2ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL6895397 0.82 SMN1; SMN2 (0.56) F2RL1SMN1; SMN2ALDH1A1MEN1KMT2A
Anisole SCHEMBL31387002 0.82 FFAR1 (0.74) FFAR1F2RL1FFAR4PLAAT3PLAAT5
SCHEMBL1566761 0.82 FFAR1 (0.73) FFAR1F2RL1POLBFFAR4ALDH1A1
Phenyl Propionic Acid SCHEMBL2153185 0.80 KEAP1 (0.70) FFAR1FFAR4PLAAT5PLAAT4SMN1; SMN2
Anisole SCHEMBL30496784 0.80 FFAR1 (0.70) FFAR1F2RL1FFAR4PLAAT3PLAAT5
SCHEMBL524586 0.80 KMT2A (0.64) FFAR1F2RL1SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595936-B1 COMPOSITION FOR EXTERNAL USE VITAMIN C60 BIORES CORP (JP) 2011-10-19 EP claimed
US-20060134095-A1 Antioxidative composition and composition for external use VITAMIN C60 BIORESEARCH CORPORATION (JP) 2006-06-22 US claimed
EP-1595936-A1 ANTIOXIDATIVE COMPOSITION AND COMPOSITION FOR EXTERNAL USE MITSUBISHI CORPORATION (JP) 2005-11-16 EP claimed
US-5585090-A MIXTURE OF METAL OXIDE FLAKE AND ULTRAVIOLET ABSORBENTENCAPSULATED POLYMER THE PROCTER & GAMBLE COMPANY (US) 1996-12-17 US claimed
EP-0503922-B1 Cosmetics having photoprotection properties MAX FACTOR KK (JP) 1995-12-20 EP claimed
EP-0503922-A2 Cosmetics having photoprotection properties MAX FACTOR K.K. (JP) 1992-09-16 EP claimed
US-12605315-B2 External skin preparation KAO CORPORATION (JP) 2026-04-21 US disclosed
US-12551424-B2 Oil-in-water type emulsification composition containing UV wavelength conversion substance SHISEIDO COMPANY, LTD. (JP) 2026-02-17 US disclosed
US-12440431-B2 Cosmetic comprising ultraviolet wavelength conversion substance SHISEIDO COMPANY, LTD. (JP) 2025-10-14 US disclosed
US-12419818-B2 External preparation KAO CORPORATION (JP) 2025-09-23 US disclosed
US-12414977-B2 Method of administering seaberry and saw palmetto extracts to inhibit 5α-reductase activity ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2025-09-16 US disclosed
US-20250268972-A1 5a-REDUCTASE INHIBITOR ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2025-08-28 US disclosed
US-20250255791-A1 POWDER COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH-CONVERTING SUBSTANCE, AND METHOD FOR PRODUCING SAME SHISEIDO COMPANY, LTD. (JP) 2025-08-14 US disclosed
EP-1364943-A1 NOVEL CYSTINE DERIVATIVES AND INHIBITORS FOR THE ACTIVATION OF INFLAMMATORY FACTORS Ajinomoto Co., Inc. (JP) 2003-11-26 EP disclosed
EP-1213006-A1 COSMETICS KANEBO, LTD. (JP) 2002-06-12 EP disclosed
JP-2000136122-A SKIN LOTION KOSE CORP 2000-05-16 JP disclosed
JP-2000136123-A SKIN LOTION KOSE CORP 2000-05-16 JP disclosed
US-5585090-A MIXTURE OF METAL OXIDE FLAKE AND ULTRAVIOLET ABSORBENTENCAPSULATED POLYMER THE PROCTER & GAMBLE COMPANY (US) 1996-12-17 US disclosed
EP-0503922-B1 Cosmetics having photoprotection properties MAX FACTOR KK (JP) 1995-12-20 EP disclosed
EP-0503922-A2 Cosmetics having photoprotection properties MAX FACTOR K.K. (JP) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605315-B2 External skin preparation TLR5, CUTA, TLR3 FFAR1 29/4885F2RL1 2027/4885POLB 261/4885
US-20060134095-A1 Antioxidative composition and composition for external use GPX4, GPX1, SOD1 FFAR1 1512/4885F2RL1 3874/4885POLB 1227/4885
US-12551424-B2 Oil-in-water type emulsification composition containing UV wavelength conversion substance PCNA, CD14, TP53 FFAR1 3769/4885F2RL1 4284/4885POLB 64/4885
US-12419818-B2 External preparation CUTA, ALOX15, HSF1 FFAR1 466/4885F2RL1 3558/4885POLB 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.